Tag Archives: 06q2

Targeting Trends Newsletter 06q2

Below are links to view the quarterly newsletter Targeting Trends. If you would like to be added to the mailing list, please complete the information on our contact page. Newsletter Highlights Chronic Pain Drug (page 2) Teaser Winners (page 2) Upcoming Meetings (page 4) Fluorescent Conjugates and Flow Cytometry (page 7)

Targeting Tools: Fluorescent Conjugates

Antibodies conjugated to fluorescent dyes are vibrant and vital tools at a scientist’s disposal. ATS currently has six fluorescent conjugates in our catalog: Cy3-labeled 192-IgG (Cat. #FL-01), FITC-labeled Anti-Saporin (Cat. #FL-02), Alexa 488-labeled 192-IgG (Cat. #FL-03), FITC-labeled Goat anti-rabbit IgG (Cat. #FL-04), Cy3- labeled anti-NGFr (Cat. #FL-05), and Cy5-labeled anti- NGFr (Cat. #FL-06). ATS also […]

Targeting Talk: Retrograde Transport

I spoke with someone from your technical service over the phone and got the impression that your product dermorphin-SAP (Cat. #IT-12) is not a retrograde and will only affect the terminals or the cells that express mu opioid receptors in the injection site in the brain. I have three questions: 1) Do you have any […]

Targeting Topics 06q2

Safety evaluation of intrathecal substance P-saporin, a targeted neurotoxin, in dogs. Allen JW, Mantyh PW, Horais K, Tozier N, Rogers SD, Ghilardi JR, Cizkova D, Grafe MR, Richter P, Lappi DA, Yaksh TL. Toxicol Sci 91(1):286-298, 2006. SP-SAP (Cat. #IT-07) has been shown to reverse neuropathic pain behavior in rodents and prevent the formation of […]

Chronic Pain Drug – Update on SP-SAP Development

ATS continues to make progress toward human clinical trials with SP-SAP. Thanks to the financial support of the National Institutes of Health, National Institute of Mental Health, preclinical studies have been completed, protocols for drug production have been written and the first of two toxicology studies is done. This first study is a GLP toxicology […]

Cover Article: Targeted Toxins in Pain

Summary of contribution to “Recontres en toxinologie, 2005” by Ronald G. Wiley, Neurology Service (127) – VA TVHS, 1310 24th Avenue, South, Nashville, TN 37212 The use of targeted toxins in neuroscience research has evolved over the past twenty-plus years from original suicide transport lesions using ricin to highly selective neuron type-specific lesions made with […]